Firefly Neuroscience will join the Russell Microcap® Index, enhancing visibility among investors after recent growth milestones.
Quiver AI Summary
Firefly Neuroscience, Inc. announced its inclusion in the Russell Microcap® Index, effective June 30, 2025. This milestone comes less than a year after the company's Nasdaq listing and reflects significant progress achieved since its reverse merger. CEO Greg Lipschitz highlighted several recent advancements, including the discovery of a cognitive brain age biomarker and the expansion of its database and intellectual property through acquiring Evoke Neuroscience. Being part of the Russell Microcap® Index is expected to enhance Firefly's visibility among institutional and retail investors, aiding its growth plans as it continues to develop its AI-driven Brain Network Analytics technology aimed at improving outcomes for patients with neurological and mental disorders.
Potential Positives
- Firefly Neuroscience, Inc. will be included in the Russell Microcap® Index, which enhances its visibility to institutional and retail investors.
- The company has made significant advancements in 2025, including discovering a breakthrough cognitive brain age biomarker and expanding its database and intellectual property through acquisition.
- The inclusion in the Russell Microcap® Index reflects the progress made since its Nasdaq listing, signaling positive growth and momentum for the company.
Potential Negatives
- Being added to the Russell Microcap® Index comes less than a year after the company's listing on Nasdaq, which may indicate a need for improved performance and stability following their recent public market entry.
- Despite recent accomplishments, the press release does not provide concrete financial metrics or performance indicators, which may raise concerns about the company's current financial health and sustainability.
- The emphasis on forward-looking statements and the associated risks may lead to investor skepticism regarding the company's projected growth and the realizable nature of its milestones.
FAQ
What is Firefly Neuroscience, Inc. known for?
Firefly is an AI company developing innovative solutions to improve brain health for those with neurological and mental disorders.
When will Firefly be added to the Russell Microcap® Index?
Firefly will be added to the Russell Microcap® Index on June 30, 2025, after the U.S. market opens.
What achievements has Firefly made in 2025?
In 2025, Firefly discovered a cognitive brain age biomarker, joined NVIDIA Connect, and expanded its database and IP portfolio.
How does Firefly's BNA™ technology benefit clinicians?
Firefly's BNA™ technology offers comprehensive insights into brain function, aiding in diagnosing mental and cognitive disorders effectively.
Why is Russell Microcap® Index membership important for Firefly?
Membership in the Russell Microcap® Index enhances Firefly's visibility among investors, crucial for executing growth plans and achieving milestones.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
– Comes less than a year after listing on Nasdaq –
KENMORE, N.Y., June 23, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that it will be added to the Russell Microcap ® Index as part of this year’s reconstitution. The additions will be made effective after the U.S. market opens on June 30, 2025.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell's U.S. indexes serve as the benchmark for approximately $10.6 trillion in assets as of the close of June 2024. Russell indexes are part of FTSE Russell, the global index provider.
“Being included among the companies that comprise the Russell indexes is a major milestone for Firefly, which we believe reflects the significant progress we have made since completing our reverse merger and listing on Nasdaq less than a year ago,” said Greg Lipschitz, CEO of Firefly. “So far in 2025 alone, we have: discovered a breakthrough cognitive brain age biomarker using our FDA-cleared BNA™ Platform; been accepted into the prestigious NVIDIA Connect program ; achieved multi-fold database, IP portfolio, and commercial footprint expansion through our acquisition of Evoke Neuroscience ; and, uncovered a powerful new way of objectively distinguishing between subjective cognitive decline, mild cognitive impairment, and dementia in Alzheimer’s patients.”
Mr. Lipschitz added, “Moving forward, our membership in the Russell Microcap ® Index should increase our visibility among both institutional and retail investors at a pivotal time as we continue to execute our growth plans and work to achieve the many potential value-creating milestones we see ahead.”
Each index within the Russell U.S. Indexes is reconstituted each year to capture the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization and grouping them according to certain criteria. Membership in the Russell Microcap
®
Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG/ERP system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
Please visit https://fireflyneuro.com/ for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
[email protected]